LDL subfractions and atherogenicity: An hypothesis from the University of Glasgow
- 1 January 1996
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 13 (7) , 379-390
- https://doi.org/10.1185/03007999609111557
Abstract
The variation in the size and atherogenicity of the low density lipoprotein (LDL) particles has attracted a great deal of recent attention. In particular, attention has focused on the role of plasma triglyceride concentrations in driving the lipoprotein exchange that determines the concentration of the smaller, denser, more atherogenic LDL fraction. In a study at Glasgow University, researchers analysed the distribution of LDL subfractions among normocholesterolaemic men, with or without coronary artery disease, survivors of myocardial infarction, and normal controls. The results showed that the risk of coronary artery disease or myocardial infarction is considerably greater in those groups with higher plasma concentrations of small, dense LDL. In a second study, eight patients with hypercholesterolaemia were treated with fenofibrate. Radioisotope tracers showed that fenofibrate shifts the distribution of LDL subfractions from small, dense, atherogenic particles towards larger, lighter, less atherogenic ones. The efficacy of fenofibrate derives from its hypotriglyceridaemic activity. Triglycerides may have further atherogenic and thrombogenic effects: they may cause endothelial cell dysfunction in the artery wall, stimulating the recruitment of macrophages into the endothelium. They may also promote the synthesis of thrombogenic mediators, suppressing local plasmin synthesis and accelerating intra-arterial fibrin deposition. This evidence has led to an increasing recognition of the central role of triglycerides in the process of atherogenesis.Keywords
This publication has 14 references indexed in Scilit:
- Remodelling of lipoproteins in transgenic mice expressing human cholesteryl ester transfer proteinBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1995
- Relation Between Cholesterol Ester Transfer Protein Activities and Lipoprotein Cholesterol in Patients With Hypercholesterolemia and Combined HyperlipidemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Plasma cholesteryl ester transfer protein and high‐density lipoproteins: new insights from molecular genetic studiesJournal of Internal Medicine, 1995
- Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease riskAtherosclerosis, 1994
- Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)The Lancet, 1992
- Effects of colestipol-niacin therapy on human femoral atherosclerosis.Circulation, 1991
- Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1985